Details of the Drug

General Information of Drug (ID: DMSJVAM)

• Drug Name: Amisulpride
• Synonyms: Aminosultopride; Amisulpiride; Amisulprida; Amisulpridum; Deniban; Socian; Solian; Amisulpride [INN]; DAN 2163; Amisulprida [INN-Spanish]; Amisulpride (INN); Amisulpridum [INN-Latin]; DAN-2163; Deniban (TN); Solian (TN); Solian, Amisulpride; SL-91.1077; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-anisamid; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide; 4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide

Indication

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Approved	[1]

• Therapeutic Class: Antipsychotic Agents
• Affected Organisms: Humans and other mammals
• ATC Code:
  N05AL05: Amisulpride
  N05AL: Benzamides
  N05A: ANTIPSYCHOTICS
  N05: PSYCHOLEPTICS
  N: NERVOUS SYSTEM
  N05AL05: Amisulpride
  N05AL: Benzamides
  N05A: ANTIPSYCHOTICS
  N05: PSYCHOLEPTICS
  N: NERVOUS SYSTEM
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 369.5
  Logarithm of the Partition Coefficient (xlogp); 1.5
  Rotatable Bond Count (rotbonds); 7
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 6
• ADMET Property:
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 39-54 mcg/L [2]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 4: low solubility and low permeability [3]
  Bioavailability: The bioavailability of drug is 48% [2]
  Clearance: The renal clearance of drug is 20.5 L/h [4]
  Elimination: Following intravenous administration, about 74% of amisulpride is excreted in urine, where 58% of the recovered dose was excreted as unchanged amisulpride [4]
  Half-life: The concentration or amount of drug in body reduced by one-half in 12 hours [5]
  Metabolism: The drug is metabolized via the de-ethylationand oxidation [2]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 46.396 micromolar/kg/day [6]
  Vd: The volume of distribution (Vd) of drug is 5.8 L/kg [7]
• Chemical Identifiers:
  Formula: C17H27N3O4S
  IUPAC Name: 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide
  Canonical SMILES: CCN1CCCC1CNC(=O)C2=CC(=C(C=C2OC)N)S(=O)(=O)CC
  InChI: InChI=1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)
  InChIKey: NTJOBXMMWNYJFB-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 2159
  ChEBI ID: CHEBI:64045
  CAS Number: 71675-85-9
  UNII: 8110R61I4U
  DrugBank ID: DB06288
  TTD ID: D03ELL
  VARIDT ID: DR01259
  ACDINA ID: D00835

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Antagonist	[8]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[9]

Molecular Expression Atlas of This Drug

• The Studied Disease: Schizophrenia
• ICD Disease Classification: 6A20

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	2.50E-02	-0.08	-0.49
P-glycoprotein 1 (ABCB1)	DTP	P-GP	9.39E-02	1.07E-01	2.80E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Amisulpride (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Amisulpride and Ivosidenib.	Acute myeloid leukaemia [2A60]	[10]
Midostaurin	DMI6E0R	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Midostaurin.	Acute myeloid leukaemia [2A60]	[11]
Gilteritinib	DMTI0ZO	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Gilteritinib.	Acute myeloid leukaemia [2A60]	[11]
Oliceridine	DM6MDCF	Major	Increased risk of prolong QT interval by the combination of Amisulpride and Oliceridine.	Acute pain [MG31]	[12]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Ivabradine.	Angina pectoris [BA40]	[13]
Bedaquiline	DM3906J	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[11]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Levalbuterol.	Asthma [CA23]	[14]
Eribulin	DM1DX4Q	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Eribulin.	Breast cancer [2C60-2C6Y]	[11]
Bosutinib	DMTI8YE	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Bosutinib.	Breast cancer [2C60-2C6Y]	[11]
PF-04449913	DMSB068	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[11]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[15]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[14]
Pasireotide	DMHM7JS	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Pasireotide.	Cushing syndrome [5A70]	[11]
Osilodrostat	DMIJC9X	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Osilodrostat.	Cushing syndrome [5A70]	[11]
Deutetrabenazine	DMUPFLI	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Deutetrabenazine.	Dystonic disorder [8A02]	[11]
Ingrezza	DMVPLNC	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Ingrezza.	Dystonic disorder [8A02]	[11]
Fostemsavir	DM50ILT	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[11]
Rilpivirine	DMJ0QOW	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[11]
TAK-491	DMCF6SX	Moderate	Additive hypotensive effects by the combination of Amisulpride and TAK-491.	Hypertension [BA00-BA04]	[16]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[17]
Crizotinib	DM4F29C	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Crizotinib.	Lung cancer [2C25]	[11]
Ceritinib	DMB920Z	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Ceritinib.	Lung cancer [2C25]	[11]
Osimertinib	DMRJLAT	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Osimertinib.	Lung cancer [2C25]	[11]
Selpercatinib	DMZR15V	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Selpercatinib.	Lung cancer [2C25]	[11]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Amisulpride and Lumefantrine.	Malaria [1F40-1F45]	[18]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Amisulpride and Vemurafenib.	Melanoma [2C30]	[17]
LGX818	DMNQXV8	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and LGX818.	Melanoma [2C30]	[11]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Amisulpride and Panobinostat.	Multiple myeloma [2A83]	[19]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Siponimod.	Multiple sclerosis [8A40]	[18]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Fingolimod.	Multiple sclerosis [8A40]	[17]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Ozanimod.	Multiple sclerosis [8A40]	[20]
Deflazacort	DMV0RNS	Moderate	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Deflazacort.	Muscular dystrophy [8C70]	[18]
Entrectinib	DMMPTLH	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Entrectinib.	Non-small cell lung cancer [2C25]	[11]
Rucaparib	DM9PVX8	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Rucaparib.	Ovarian cancer [2C73]	[11]
Triclabendazole	DMPWGBR	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Triclabendazole.	Parasitic worm infestation [1F90]	[11]
Opicapone	DM1BKA6	Moderate	Antagonize the effect of Amisulpride when combined with Opicapone.	Parkinsonism [8A00]	[21]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Amisulpride and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[22]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Amisulpride and Lefamulin.	Pneumonia [CA40]	[23]
Degarelix	DM3O8QY	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Degarelix.	Prostate cancer [2C82]	[11]
Enzalutamide	DMGL19D	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Enzalutamide.	Prostate cancer [2C82]	[11]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Amisulpride and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[17]
Triptorelin	DMTK4LS	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[11]
Pitolisant	DM8RFNJ	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Pitolisant.	Somnolence [MG42]	[11]
Telavancin	DM58VQX	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[11]
Lenvatinib	DMB1IU4	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Lenvatinib.	Thyroid cancer [2D10]	[11]
Cabozantinib	DMIYDT4	Major	Increased risk of ventricular arrhythmias by the combination of Amisulpride and Cabozantinib.	Thyroid cancer [2D10]	[11]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Hydrochloric acid	E00015	313	Acidulant
Citric acid monohydrate	E00271	22230	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Sodium chloride	E00077	5234	Diluent; Tonicity agent
Sodium citrate dihydrate	E00369	71474	Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Water	E00035	962	Solvent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Amisulpride 5mg/2ml solution	5mg/2ml	Solution	Intravenous
Amisulpride 10mg/4ml solution	10mg/4ml	Solution	Intravenous

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 963).
• [2] Boison D, Yegutkin GG: Adenosine Metabolism: Emerging Concepts for Cancer Therapy. Cancer Cell. 2019 Dec 9;36(6):582-596. doi: 10.1016/j.ccell.2019.10.007.
• [3] BDDCS applied to over 900 drugs
• [4] FDA Approved Drug Products: BARHEMSYS (amisulpride) injection, for intravenous use
• [5] Amisulpride: a review of its use in the management of schizophrenia. Drugs. 2001;61(14):2123-50. doi: 10.2165/00003495-200161140-00014.
• [6] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [7] Summary of Product Characteristics: Amisulpride Oral Tablets
• [8] Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389-409.
• [9] Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
• [10] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [11] Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
• [12] Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
• [13] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [14] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [15] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [16] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
• [17] Canadian Pharmacists Association.
• [18] Cerner Multum, Inc. "Australian Product Information.".
• [19] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [20] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [21] Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
• [22] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [23] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.